Skip to content

Project Looking-Glass Evaluation

Evaluation of Novel CT Imaging for Simulation on a Linear Accelerator

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06056063
Enrollment
27
Registered
2023-09-28
Start date
2023-11-19
Completion date
2026-09-30
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cone-Beam Computed Tomography

Brief summary

Pilot study to validate the new design and workflow of Cone-Beam CT imaging for radiation therapy treatment simulation.

Detailed description

This study is a prospective, non-randomized imaging evaluation study. A cohort of subjects undergoing standard of care radiation therapy will be selected based on malignancies from six disease sites. The Halcyon 4.0 images acquired in place of standard evaluation CT scans during the course of treatment will be used for target volume delineation and normal structures segmentation. Treatment plans will be recalculated based on the Halcyon 4.0 images from this system and compared to the original treatment plan. Dose differences will be evaluated. Two-tailed t-test will be used to compare the statistical significance of the dosimetric results as well as the volumetric differences among target volume and the volumes of organs at risk.

Interventions

DEVICEHalcyon 4.0

This Halcyon 4.0 is a new imaging hardware recently developed by Varian and approved by the FDA.

Sponsors

Varian Medical Systems
CollaboratorINDUSTRY
Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects will be treated with external beam radiotherapy at the Perelman Center for Advanced Medicine for any of the following malignancies: head-and-neck, thoracic, breast, gastrointestinal, gynecologic, or genitourinary. * Age ≥ 18 years * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician * Availability of a complete set of treatment plans, including CT simulation images, target and normal structure contours, and radiation treatment prescriptions

Exclusion criteria

* Subjects who are pregnant or have plans for pregnancy during the period of treatment. * Any malignancy not stated above. * Those unable to be treated on any linear accelerator (whether Truebeam™ or Halcyon™) unit either due to subject anatomy or treatment plan. * Those undergoing proton therapy.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability of image quality of the novel cone-beam CT imaging system compared to that of standard cone-beam CT imaging and that of conventional fan beam CT imaging used for radiotherapy planning purposes1 yearQualitative results (Yes is acceptable/No is not acceptable) will be reported as tabulated data to demonstrate the differences from the standard practice
Ease of use of the novel cone-beam CT imaging system compared to standard practice1 yearEase of use of the novel cone-beam CT imaging system on a scale of 1 (very easy to use, no difficulty) to 5 (unable to use due to difficulty)
Quantitative comparison of the image quality of the novel cone-beam CT imaging system to that of standard cone-beam CT imaging and that of conventional fan beam CT imaging used for radiotherapy planning purposes1 yearA scale of Better/Worse/Equal will be used for metrics such as CBCT image artifact, CBCT image quality for OAR contouring, CBCT image quality for GTV contouring, motion artifacts, auto-segmentation ability, electron density similarity
Statistical significance of quantitative comparison of the image quality of the novel cone-beam CT imaging system and standard practice1 yearFor situations that the quantitative results will be measured, such as the structure volume or predicted electron densities etc., statistical significance will be calculated.

Secondary

MeasureTime frameDescription
Evaluation of the suitability and workflow of the novel CBCT images for radiation treatment planning and dose calculation.1 yearThe secondary endpoint is to compare the accuracies of dose and volume calculations to the standard arm using the conventional CT simulation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026